Emerging therapeutic strategies for obesity management for cardiovascular risk reduction in resource-limited settings: A review focusing on semaglutide
Narra X · 16.11.2026 · 4 (3) · e381
DOI: 10.52225/narrax.v4i3.381 ↗Kurz gefasst
Fachartikel in der Zeitschrift Narra X, online erschienen am 16.11.2026. Verfasst von Habibie Arifianto und 9 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Obesity represents a major contributor to cardiovascular disease burden, particularly in resource-limited settings where prevention, early detection, and long-term management remain challenging. Excess adiposity promotes cardiometabolic dysfunction through interconnected pathways involving insulin resistance, chronic low-grade inflammation, dyslipidemia, neurohormonal activation, and adverse cardiac remodeling, ultimately increasing the risk of heart failure, ischemic heart disease, stroke, and major adverse cardiovascular events. Among emerging therapeutic targets, incretin-based pathways have gained particular attention because they address both weight reduction and cardiovascular risk modification. Semaglutide, a glucagon-like peptide-1 receptor agonist, has become one of the most clinically relevant agents in this field, with evidence showing substantial reductions in body weight and improvements in glycemic control, visceral adiposity, systemic inflammation, blood pressure, and cardiometabolic risk markers. Data further support the potential role of semaglutide in reducing cardiovascular events, including among individuals with obesity and established cardiovascular disease without type 2 diabetes. The aim of the review is to synthesize current mechanistic and clinical evidence on semaglutide as an emerging therapeutic strategy in obesity management for cardiovascular risk reduction, while briefly contextualizing its role among other novel anti-obesity pharmacotherapies. Particular attention is also given to the relevance of semaglutide in resource-limited settings. Understanding organ-specific mechanisms and prioritizing scalable interventions may support more effective cardiovascular disease risk reduction strategies in obesity within resource-constrained healthcare systems.
Zitieren
APA
Arifianto, H., Lukito, A. A., Santoso, A., Ambari, A. M., Octaviono, Y. H., Erwinanto, E., Tiksnadi, B. B., Danny, S. S., Bakhriansyah, J., & Haryadi, H. (2026). Emerging therapeutic strategies for obesity management for cardiovascular risk reduction in resource-limited settings: A review focusing on semaglutide. Narra X, 4(3), e381. https://doi.org/10.52225/narrax.v4i3.381
Vancouver
Arifianto H, Lukito AA, Santoso A, Ambari AM, Octaviono YH, Erwinanto E, et al. Emerging therapeutic strategies for obesity management for cardiovascular risk reduction in resource-limited settings: A review focusing on semaglutide. Narra X. 2026;4(3):e381. doi:10.52225/narrax.v4i3.381
BibTeX
@article{Arifianto2026,
author = {Arifianto, Habibie and Lukito, Antonia A. and Santoso, Anwar and Ambari, Ade M. and Octaviono, Yudi H. and Erwinanto, Erwinanto and Tiksnadi, Badai B. and Danny, Siska S. and Bakhriansyah, Jordan and Haryadi, Haryadi},
title = {Emerging therapeutic strategies for obesity management for cardiovascular risk reduction in resource-limited settings: A review focusing on semaglutide},
journal = {Narra X},
year = {2026},
volume = {4},
number = {3},
pages = {e381},
doi = {10.52225/narrax.v4i3.381}
}
EUVIMED